Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Wasamoto

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Investigational New Drugs|June 24, 2022
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancerHisao Imai, Yoshiaki Nagai, Hiroyuki Minemura, et al.
Thoracic Cancer|May 26, 2022
Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapyTaisuke Araki, Kazunari Tateishi, Masamichi Komatsu, et al.
Thoracic Cancer|September 5, 2022
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survivalKen Masubuchi, Hisao Imai, Satoshi Wasamoto, et al.
Journal of Cancer Research and Clinical Oncology|December 20, 2019
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancerHisao Imai, Satoshi Wasamoto, Ou Yamaguchi, et al.
Thoracic Cancer|July 20, 2023
Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexedHisao Imai, Satoshi Wasamoto, Takeshi Tsuda, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2020
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancerOu Yamaguchi, Hisao Imai, Hiroyuki Minemura, et al.
Thoracic Cancer|August 27, 2020
Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysisHisao Imai, Hiroyuki Minemura, Takayuki Kishikawa, et al.
Frontiers in Oncology|February 6, 2023
Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancerSatoshi Wasamoto, Hisao Imai, Takeshi Tsuda, et al.
Oncology|August 20, 2023
Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-PaclitaxelFuyumi Nishihara-Kato, Hisao Imai, Takeshi Tsuda, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Investigational New Drugs|June 24, 2022
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancerHisao Imai, Yoshiaki Nagai, Hiroyuki Minemura, et al.
Thoracic Cancer|May 26, 2022
Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapyTaisuke Araki, Kazunari Tateishi, Masamichi Komatsu, et al.
Thoracic Cancer|September 5, 2022
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survivalKen Masubuchi, Hisao Imai, Satoshi Wasamoto, et al.
Journal of Cancer Research and Clinical Oncology|December 20, 2019
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancerHisao Imai, Satoshi Wasamoto, Ou Yamaguchi, et al.
Thoracic Cancer|July 20, 2023
Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexedHisao Imai, Satoshi Wasamoto, Takeshi Tsuda, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2020
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancerOu Yamaguchi, Hisao Imai, Hiroyuki Minemura, et al.
Thoracic Cancer|August 27, 2020
Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysisHisao Imai, Hiroyuki Minemura, Takayuki Kishikawa, et al.
Frontiers in Oncology|February 6, 2023
Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancerSatoshi Wasamoto, Hisao Imai, Takeshi Tsuda, et al.
Oncology|August 20, 2023
Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-PaclitaxelFuyumi Nishihara-Kato, Hisao Imai, Takeshi Tsuda, et al.
Pageof 2